Eli Lilly to Sign $2 Billion AI Drug Development Deal with Hong Kong Biotech

Global pharmaceutical company Eli Lilly is set to sign a $2 billion deal for AI-driven drug development with a Hong Kong-based biotech firm, as major pharmaceutical companies increase their search for new medicines in China.